16-18 July 2018 | Boston

Register interest for 2019 and the event series 

Recombinetics Inc.

Founded in 2008, Recombinetics has developed gene-edited animals for biomedical and food production purposes and is currently generating commercial and collaborative revenues. The Company’s technology platform supports three business lines: Surrogen, Regenevida, and Acceligen.

Surrogen develops humanized swine models for biomedical research and human therapeutics, with a focus on humanized swine models for cancer, cardiac and kidney disease. Regenevida is engaged in collaborative partnerships with leading medical and transplantation institutions to advance regenerative medicine programs to grow human cells and tissues, and eventually organs, in gene-edited pigs. The division has made significant research breakthroughs in eye, liver, heart tissues and other organs targets.

Acceligen uses accelerated precision breeding to create elite, gene-edited animals with naturally-occurring traits to enhance their health, well-being, and productivity. It has created the world’s first naturally hornless cows and has signed agreements with global genetics companies to commercialize its naturally hornless (polled) and naturally cool (SLICK/Thermotolerant) cattle as well as castration-free swine. Other traits are under development for cattle, pigs, and fish.

Recombinetics has a global intellectual property portfolio, with 18 patents issued and more than 200 patent filings on gene-editing methods, traits, and novel reproduction methods in animals.

Learn more at Recombinetics.com.